{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:04:43Z","timestamp":1789772683366,"version":"4.0.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00111","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T04:32:37Z","timestamp":1550032357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs"],"prefix":"10.3389","volume":"10","author":[{"given":"Cristina","family":"Scavone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liberato","family":"Berrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.stem.2016.08.012","article-title":"Overcoming challenges facing advanced therapies in the EU market.","volume":"19","author":"Abou-El-Enein","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000357131","article-title":"Unmet therapeutic needs in eosinophilic esophagitis.","volume":"32","author":"Aceves","year":"2014","journal-title":"Dig. Dis."},{"key":"B3","year":"2017","journal-title":"Determina 16 Febbraio."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20165644","article-title":"Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies.","volume":"49","author":"Andrade","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial.","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/14740338.2017.1388371","article-title":"Drugs approved for the treatment of multiple sclerosis: review of their safety profile.","volume":"16","author":"Auricchio","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1183\/13993003.51387-2007","article-title":"Global strategy for asthma management and prevention: GINA executive summary.","volume":"31","author":"Bateman","year":"2008","journal-title":"Eur. Respir. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of us food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s13300-014-0079-6","article-title":"Assessment of unmet clinical need in type 2 diabetic patients on conventional therapy in the UK.","volume":"5","author":"Bennett","year":"2014","journal-title":"Diabetes Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.15171\/ijhpm.2017.104","article-title":"The response to and impact of the ebola epidemic: towards an agenda for interdisciplinary research.","volume":"7","author":"Calnan","year":"2017","journal-title":"Int. J. Health Policy Manag."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1517\/14740338.2014.941804","article-title":"Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.","author":"Capuano","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/0976-500X.184768","article-title":"Expedited drug review process: fast, but flawed.","volume":"7","author":"Chary","year":"2016","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S2213-2600(18)30194-2","article-title":"Tralokinumab unsuccessful for management of severe, uncontrolled asthma.","volume":"6","author":"Chung","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijcard.2017.11.075","article-title":"Polypill hypertension and medication adherence: the solution strategy?","volume":"252","author":"Cimmaruta","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer\u2019s disease: strategies for disease modification.","volume":"9","author":"Citron","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.12860","article-title":"Achievements, challenges and unmet needs for haemophilia patients with inhibitors: report from a symposium in paris, france on 20 november 2014.","author":"Dargaud","year":"2016","journal-title":"Haemophilia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market.","volume":"7","author":"Ecker","year":"2015","journal-title":"MAbs"},{"key":"B19","year":"2017","journal-title":"Prime Priority Medicines."},{"key":"B20","year":"2018","journal-title":"Accelerated Assessment."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3","article-title":"Anti-IL5 therapies for asthma.","volume":"21","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40273-017-0559-4","article-title":"The implementation of managed entry agreements in central and eastern europe: findings and implications.","volume":"35","author":"Ferrario","year":"2017","journal-title":"Pharmacoeconomics."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0307-1","article-title":"Gene suppression approaches to neurodegeneration.","volume":"9","author":"Ghosh","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"B25","author":"Kaplan","year":"2013","journal-title":"Priority Medicines for Europe and the World 2013 Update."},{"key":"B26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/JBM.S103796","article-title":"Many factor VIII products available in the treatment of hemophilia a: an embarrassment of riches?","volume":"8","author":"Lieuw","year":"2017","journal-title":"J. Blood Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/DBP.0000000000000363","article-title":"Unmet health services needs among us children with developmental disabilities: associations with family impact and child functioning.","volume":"37","author":"Lindly","year":"2016","journal-title":"J. Dev. Behav. Pediatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40273-017-0590-5","article-title":"Budget impact analysis of PCSK9 inhibitors for the management of adult patients with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.","volume":"36","author":"Mallya","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13037nr4c","article-title":"Identifying and addressing unmet therapeutic needs in MS.","volume":"76","author":"Markowitz","year":"2015","journal-title":"J. Clin. Psychiatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.phrs.2017.07.005","article-title":"Can causality assessment fulfill the new european definition of adverse drug reaction? a review of methods used in spontaneous reporting.","volume":"123","author":"Mascolo","year":"2017","journal-title":"Pharmacol. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jmig.2008.08.015","article-title":"Unmet therapeutic needs for uterine myomas.","volume":"16","author":"Miller","year":"2009","journal-title":"J. Minim. Invasive Gynecol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1573399810666141224121927","article-title":"Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development.","volume":"11","author":"Mittermayer","year":"2015","journal-title":"Curr. Diabetes Rev."},{"key":"B33","first-page":"e4","article-title":"Toward a definition of pharmaceutical innovation.","volume":"2","author":"Morgan","year":"2008","journal-title":"Open Med."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2017.00055","article-title":"Addressing pressing needs in the development of advanced therapies.","volume":"5","author":"Morrow","year":"2017","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3837","article-title":"Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.","volume":"358","author":"Mostaghim","year":"2017","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1562-8","article-title":"Is real world evidence influencing practice? a systematic review of CPRD research in NICE guidances.","volume":"16","author":"Oyinlola","year":"2016","journal-title":"BMC Health Serv. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/2040620716652289","article-title":"Recent advances and novel treatment paradigms in acute lymphocytic leukemia.","volume":"7","author":"Papadantonakis","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1586\/17512433.2015.1028918","article-title":"White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.","volume":"8","author":"Papaluca","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines4030014","article-title":"Antibody-drug conjugates for cancer therapy.","volume":"4","author":"Parslow","year":"2016","journal-title":"Biomedicines"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.euroneuro.2015.06.009","article-title":"European child and adolescent clinical psychopharmacology network. unmet needs in paediatric psychopharmacology: present scenario and future perspectives.","volume":"25","author":"Persico","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0092","article-title":"Weight-change trajectories of pediatric outpatients treated with risperidone or aripiprazole in a naturalistic setting.","author":"Pozzi","year":"2018","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2016.1229301","article-title":"Second generation antipsychotics in \u2019real-life\u2019 paediatric patients. adverse drug reactions and clinical outcomes of drug switch.","author":"Rafaniello","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/tpj.2017.38","article-title":"The predictive value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.","volume":"18","author":"Rafaniello","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"CNP task force. report by the ACNP task force on response, and remission in major depressive disorder.","volume":"31","author":"Rush","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"B45","first-page":"373","article-title":"Rewarding innovation in drug development.","volume":"7","author":"Saadi","year":"2014","journal-title":"Am. Health Drug Benefits."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001880","article-title":"Development of newborn and infant vaccines.","volume":"3","author":"Sanchez-Schmitz","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-0930-y","article-title":"Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease.","volume":"16","author":"Sarri","year":"2018","journal-title":"Health Qual. Life Outcomes."},{"key":"B48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/MCP.0000000000000340","article-title":"Novel targets of omalizumab in asthma.","volume":"23","author":"Sattler","year":"2017","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.clinthera.2018.09.015","article-title":"On the policy of the italian government in the discovery, development, and access to medicines.","volume":"40","author":"Scavone","year":"2018","journal-title":"Clin. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.11.002","article-title":"Strengths, weaknesses and future challenges of biosimilars\u2019 development. an opinion on how to improve the knowledge and use of biosimilars in clinical practice.","volume":"126","author":"Scavone","year":"","journal-title":"Pharmacol. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.phrs.2017.02.006","article-title":"Biosimilars in the european union from comparability exercise to real world experience: what we achieved and what we still need to achieve.","volume":"119","author":"Scavone","year":"","journal-title":"Pharmacol. Res."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00607","article-title":"BIO-cam group. safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in campania region (italy): bio-cam observational study.","volume":"8","author":"Scavone","year":"","journal-title":"Front. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cpt.814","article-title":"Critical review of umbrella, basket, and platform designs for oncology clinical trials.","volume":"102","author":"Simon","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2016.06.016","article-title":"Patient stratification and the unmet need in asthma.","volume":"169","author":"Swedin","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/jac\/dkq096","article-title":"Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.","volume":"65","author":"Taiwo","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/CCRPM.S7793","article-title":"Omalizumab: clinical use for the management of asthma.","volume":"6","author":"Thomson","year":"2012","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"B57","year":"2014","journal-title":"Guidance for Industry Expedited Programs for Serious Conditions \u2013 Drugs and Biologics."},{"key":"B58","year":"2018","journal-title":"FDA Approves Larotrectinib for Solid Tumors with Ntrk Gene Fusions."},{"key":"B59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3238\/arztebl.2012.0117","article-title":"New drugs: evidence relating to their therapeutic value after introduction to the market.","volume":"109","author":"Ujeyl","year":"2012","journal-title":"Dtsch. Arztebl. Int."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00497","article-title":"Adaptive pathways: possible next steps for payers in preparation for their potential implementation.","volume":"8","author":"Vella Bonanno","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1210","article-title":"Using real world data to extrapolate evidence from randomized controlled trials.","author":"Wang","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418776932","article-title":"Antisense oligonucleotides in neurological disorders.","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0963689717735411","article-title":"Cell therapy for parkinson\u2019s disease.","volume":"26","author":"Yasuhara","year":"2017","journal-title":"Cell Transplant"},{"key":"B64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3892\/br.2018.1049","article-title":"Induced pluripotent stem cells in rat models of parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"8","author":"Zhang","year":"2018","journal-title":"Biomed. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T04:32:39Z","timestamp":1550032359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":64,"alternative-id":["10.3389\/fphar.2019.00111"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00111","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"article-number":"111"}}